Moderna and Merck are developing an experimental melanoma vaccine with partners, while concerns about AI models are impacting Gartner's business.

The entities involved

• Moderna →

  American biotechnology company

  • Analyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Mon 17:09
  • Positive test results were reported for Moderna's flu vaccine.Sun 15:33
• Merck →

  public company in Indonesia

  • Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Sat 17:22
  • Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.Fri 18:13
• Gartner →

  company

  • SPS Commerce utilized market data that was cited by Gartner.Mon 10:36
  • Global Legal Entity Identifier Foundation proposes verifiable LEI as a trust solution for AI governance, alongside a prediction on AI agent adoption.Mon 05:21

Related events

• Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.Sep 11
• Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.Aug 25
• Moderna and Merck co-developed an experimental cancer vaccine, while also forming a partnership regarding tensor processing units with Google and Marvell Technology.Aug 19
• Analyst comments on industry trends regarding Moderna's competition in the cancer vaccine market.Aug 26
• Moderna and Merrill jointly developed skin cancer vaccine trials.Aug 25